Friday, November 13, 2026

SPAC Liquidation Wave Hits Global Markets as Trust Fund Structures Show 3% Loss Pattern

AltEnergy Acquisition Corp faces trust fund liquidation if no merger closes before its charter deadline, joining 15% of SPACs launched globally since 2020 that dissolved without deals. Trust fund returns average 97.2% of IPO proceeds across markets, with legal and administrative costs eroding investor capital. The structure exposes conflicts between sponsors risking total equity loss and public shareholders locked in low-yield government securities.

SPAC Liquidation Wave Hits Global Markets as Trust Fund Structures Show 3% Loss Pattern
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

AltEnergy Acquisition Corp must complete a business combination before its charter expires or liquidate its trust fund, returning assets to shareholders at approximately 97% of initial public offering value. Legal fees, accounting costs, and insurance premiums reduce per-share distributions by 2-4% across the global SPAC sector.

Market data from 2020-2023 shows 15% of SPACs worldwide liquidated without completing mergers. Trust fund mechanics mandate that IPO proceeds remain in government securities or money market instruments under SEC rules, protecting capital from operational misuse but generating minimal returns during merger searches that can extend beyond two years.

The trust structure creates asymmetric risk exposure. SPAC sponsors purchase founder shares at nominal prices that become worthless without completed transactions, while public shareholders retain redemption rights to reclaim pro-rata trust assets before merger votes. Post-liquidation distributions average 97.2% of IPO proceeds, with variance depending on time to dissolution and accumulated expenses.

AltEnergy's energy infrastructure focus compounds timeline pressure. Due diligence for energy sector targets requires extensive regulatory review across multiple jurisdictions, compressing negotiation windows before charter expiration. Charter extension votes trigger redemption waves that shrink available acquisition capital, with some SPACs losing 60-80% of trust balances through shareholder exits.

Regulatory frameworks vary across markets but converge on disclosure-only oversight. The SEC requires quarterly trust fund balance reporting without expense caps, while trustees follow account agreements without fiduciary duties to maximize returns. International SPAC structures in European and Asian markets show similar trust erosion patterns despite different regulatory regimes.

The mechanism creates principal-agent conflicts as management teams exhaust charter periods pursuing marginal deals. Sponsors prioritize transaction completion over target quality to avoid total equity loss, while shareholders bear opportunity costs of capital locked at sub-1% yields in government securities. Longer merger searches accumulate higher expense ratios through legal fees and D&O insurance premiums, with trusts older than 24 months showing 3-5% erosion rates.


Sources:
1 Globe Newswire, "Eos Energy Honors Outgoing Chair Russ Stidolph for Years of Leadership and Investment and Appoints I" (December 22, 2025)

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com